Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global second quarter net sales of OLYSIO® (simeprevir) amounted to 264 MUSD, of which 50 MUSD were sales in the USA.
The royalty for the second quarter amounted to 166 MSEK (17.9 MEUR). Medivir’s royalties based on sales for the second quarter are calculated from the second royalty tier. In addition Medivir has received a currency adjustment of 24 MSEK (2.6 MEUR) related to 2014. The total royalty income reported for the second quarter will therefore amount to 190 MSEK (20.5 MEUR).
| OLYSIO® global net sales | Sales in MUSD | ||
| Market | Q2 -2015 | Q2-2014 | Change |
| US | 50 | 725 | -93% |
| RoW | 214 | 106 | 101% |
| Total global net sales MUSD | 264 | 832 | -68% |
Medivir will publish its second quarter report on August 20, 2015 at 8.30 CET followed by a conference call for investors, analysts and the media at 14.00 CET. More information about the conference call/webcast will be posted at www.medivir.com.
For more information please contact:
Ola Burmark, CFO, Medivir AB, mobile: +46 725 480 580
Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 14.00 CET on 14 July 2015.
About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.